Pfizer's Latest International Pfiascos - Charges of Anti-Competitive Practices, Inflated Prices, Deception and Secrecy
Many big health care organizations seem to just be unable to keep out of trouble, and the bigger they are, the more kinds of trouble. Pfizer Inc, considered to be one of the world's largest pharmaceutical companies, has supplied us with plenty of stories. Enough new stories about Pfizer have accumulated since last year to do a roundup. Presented in chronological order....Italy Demands Damages from Pfizer for Anti-Trust ViolationsThis story came out in May, 2014, via Reuters,Italy said on Wednesday it was seeking more than a billion euros in damages from multinational drug companies following a ruling by the country's antitrust authority that their policies had been detrimental to Italy's national health service.The health ministry said in a statement it was requesting a total 1.2 billion euros ($1.6 billion) from Novartis and Roche for the damages incurred in 2012-2014, and was requesting 14 million euros from Pfizer.It cited several recent antitrust rulings that the companies' repeated anti-competitive actions had caused the national health service 'considerable damage'.The specific charges against Pfizer were:Italy's state council, the highest administrative court, in February ruled that Pfizer had abused its dominant position relating to the glaucoma drug Xalatan 'with a clear and persistent intention to suppress competition'.At least in English language news sources, I have not seen how this turned out, but note that this was apparently an ad...
Worldwide use of pneumococcal conjugate vaccines (PCVs) had reduced the incidence of pneumonia and invasive pneumococcal disease (IPD) in children.1,2 Despite increasing vaccine coverage and a reduction in the prevalence of IPD, Streptococcus pneumoniae remains a significant cause of non-Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (HUS) in children.3 HUS is characterized by the presence of the clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.
CONCLUSION: In hypertensive and diabetic patients, higher OPG values were associated with impaired LA function assessed by 2D-STE. In this high-risk patient group, serum OPG can be used as a risk predictor for LA mechanical dysfunction. PMID: 32462219 [PubMed - as supplied by publisher]
Publication date: September 2020Source: Epilepsy &Behavior, Volume 110Author(s): Christopher Ll Morgan, Stefan Varga, Wan Tsong, Sara Jenkins-Jones, Sarah Holden
Publication date: Available online 28 May 2020Source: The LancetAuthor(s): Nelson Lee, Allison McGeer
Publication date: July 2020Source: American Heart Journal, Volume 225Author(s): Harvey D. White, Ralph A.H. Stewart, Anthony J. Dalby, Amanda Stebbins, Christopher P. Cannon, Andrzej Budaj, Ales Linhart, Prem Pais, Rafael Diaz, Philippe Gabriel Steg, Sue Krug-Gourley, Christopher B. Granger, Judith S. Hochman, Wolfgang Koenig, Robert A. Harrington, Claes Held, Lars Wallentin, on behalf of the STABILITY Investigators
AbstractGlioma is the most common primary tumor of the nervous system, and approximately 50% of patients exhibit the most aggressive form of the cancer, glioblastoma. Currently, considerable research in glioblastoma therapeutics is aimed at developing vaccines or drugs to target key molecules for combating this disease. Studies on plant natural products from spices, vegetables, fruits, teas, and traditional medicinal herbs display that these plant-derived natural products can act as effective antioxidant and anti-tumor agents. The advancements in metabolomics and in genomics have enabled researchers to better evaluate the ...
Moderna Inc said on Friday it had started dosing patients in a mid-stage study with its experimental coronavirus vaccine and eventually plans to enroll 600 patients for the trial.
Scientists are developing drugs to stop the coronavirus. Here's what's promising and what isn't.
Publication date: Available online 28 May 2020Source: Veterinary MicrobiologyAuthor(s): Yuying Han, Libao Xie, Mengqi Yuan, Yuteng Ma, Huimin Sun, Yuan Sun, Yongfeng Li, Hua-Ji Qiu
More News: Appendicitis | Asbestosis | Atorvastatin Calcium | Biotechnology | Blogging | Child Abuse | Children | Cholesterol | Clinical Trials | Detrol | Drugs & Pharmacology | Enbrel | Epilepsy | Gabapentin | Geodon | Glaucoma | Government | Health | Health Management | Health Medicine & Bioethics Commentators | Hemorrhoids | History of Medicine | Hormones | Latanoprost | Lawsuits | Legislation | Linezolid | Lipitor | Lyrica | Marketing | Medicaid | Medical Ethics | Meningitis Vaccine | National Health Service (NHS) | Neurology | Neurontin | Neuroscience | Pantoprazole | Pediatrics | Pensions | Pfizer | Phenytoin | Pneomococcal Vaccine | Profits and Losses | Proton Pump Inhibitors PPIs | Protonix | Research | Salaries | Science | Statin Therapy | Substance Abuse | UK Health | Vaccines | Websites | Ziprasidone | Zivast | Zyvox